Zuclopenthixol decanoate pharmacokinetics

Co-injection of Clopixol-Acuphase and Clopixol Depot: For patients with exacerbation of chronic psychoses, Clopixol-Acuphase and Clopixol Depot can be mixed in a syringe and given as one injection (co-injection). Since Clopixol-Acuphase and Clopixol Depot are dissolved in the same vehicle, mixing will not affect the pharmacokinetics of either formulation and will allow the administration of an acute and maintenance dose with one injection. Subsequent doses of Clopixol Depot and the interval between injections should be adjusted according to the patient’s response. Clopixol-Acuphase cannot be mixed with other antipsychotic depot formulations.

Zuclopenthixol has no mutagenic or carcinogenic potential. In a rat oncogenecity study 30 mg/kg/day for two years (top dosage) resulted in slight non-statistical increases in the incidence of mammary adenocarcinomas, pancreatic islet cell adenomas, carcinomas in females and thyroid parafollicular carcinomas. The slight increase in the incidence of these tumors is a common finding for D 2 antagonists, which increase prolactin secretion when administered to rats. The physiological differences between rats and humans with regard to prolactin make the clinical significance of these findings unclear, but it is accepted as not predicting an oncogenic risk in patients.

Zuclopenthixol decanoate pharmacokinetics

zuclopenthixol decanoate pharmacokinetics

Media:

zuclopenthixol decanoate pharmacokineticszuclopenthixol decanoate pharmacokineticszuclopenthixol decanoate pharmacokineticszuclopenthixol decanoate pharmacokineticszuclopenthixol decanoate pharmacokinetics

http://buy-steroids.org